18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma:results of a Nordic/US intergroup study

Autor: Victor Vishwanath Iyer, Morton Coleman, Paw Jensen, Mikael Eriksson, Dorte Gillstrom, Dominick Lamonica, Myron S. Czuczman, Per Boye Hansen, Annika Loft, Marko Seppänen, Helle W. Hendel, Martin Hutchings, Karen Juul Mylam, Karin Hjorthaug, Sirpa Leppä, Peter de Nully Brown, Lars Møller Pedersen, Harald Holte, Lale Kostakoglu, Sirkku Jyrkkiö, Anne Lerberg Nielsen, Louis F. Diehl
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
Cancer Research
medicine.medical_treatment
Denmark
Tomography
X-Ray Computed/methods
Computed tomography
Multimodal Imaging
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Tissue Distribution
Prospective Studies
Finland
Aged
80 and over
medicine.diagnostic_test
Norway
Hematology
Diffuse large B-cell lymphoma
Middle Aged
Prognosis
3. Good health
Survival Rate
Lymphoma
Large B-Cell
Diffuse/drug therapy
Oncology
030220 oncology & carcinogenesis
Female
Tomography
Lymphoma
Large B-Cell
Diffuse
Adult
Predictive value
Standardized uptake value
03 medical and health sciences
Young Adult
Chemoimmunotherapy
Fluorodeoxyglucose F18
medicine
Deauville 5-point scale
Humans
In patient
Aged
Neoplasm Staging
Sweden
Chemotherapy
Fluorodeoxyglucose F18/pharmacokinetics
business.industry
medicine.disease
Positron-Emission Tomography/methods
United States
Lymphoma
Interim PET/CT
Positron-Emission Tomography
Radiopharmaceuticals/pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Radiopharmaceuticals
Nuclear medicine
business
Tomography
X-Ray Computed
Interim PET/CT predictive value diffuse large B-cell lymphoma Deauville 5-point scale NON-HODGKINS-LYMPHOMA SUV-BASED ASSESSMENT EARLY F-18-FDG PET PROGNOSTIC VALUE AGGRESSIVE LYMPHOMA INTERIM-PET FDG-PET INTERNATIONAL WORKSHOP RESPONSE CRITERIA RITUXIMAB
030215 immunology
Follow-Up Studies
Zdroj: Juul Mylam, K, Kostakoglu, L, Hutchings, M, Coleman, M, Lamonica, D, Czuczman, M S, Diehl, L F, Nielsen, A L, Jensen, P, Loft, A, Hendel, H W, Iyer, V, Leppa, S, Jyrkkio, S, Holte, H, Eriksson, M, Gillstrøm, D, Hansen, P B, Seppanen, M, Hjorthaug, K, Brown, P N & Pedersen, L M 2015, ' 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma : results of a Nordic/US intergroup study ', Leukemia and Lymphoma, vol. 56, no. 7, pp. 2005-2012 . https://doi.org/10.3109/10428194.2014.975800
Mylam, K J, Kostakoglu, L, Hutchings, M, Coleman, M, Lamonica, D, Czuczman, M S, Diehl, L F, Nielsen, A L, Jensen, P, Loft, A, Hendel, H W, Iyer, V, Leppä, S, Jyrkkiö, S, Holte, H, Eriksson, M, Gillstrøm, D, Hansen, P B, Seppänen, M, Hjorthaug, K, Brown, P D N & Pedersen, L M 2015, ' 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma : results of a Nordic/US intergroup study ', Leukemia and Lymphoma, vol. 56, no. 7, pp. 2005-2012 . https://doi.org/10.3109/10428194.2014.975800
DOI: 10.3109/10428194.2014.975800
Popis: We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
Databáze: OpenAIRE
Externí odkaz: